Who are Conventional adjuvant FOLFOX's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conventional-adjuvant-folfox.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Conventional adjuvant FOLFOX — Competitive Intelligence Brief

Conventional adjuvant FOLFOX (Conventional adjuvant FOLFOX) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen (combination of antimetabolite and platinum agent). Area: Oncology.

phase 3 Chemotherapy regimen (combination of antimetabolite and platinum agent) Thymidylate synthase (5-FU); DNA (oxaliplatin cross-linking) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Conventional adjuvant FOLFOX (Conventional adjuvant FOLFOX) — Kyungpook National University Hospital. FOLFOX is a chemotherapy regimen that combines fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce cell death in cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Conventional adjuvant FOLFOX TARGET	Conventional adjuvant FOLFOX	Kyungpook National University Hospital	phase 3	Chemotherapy regimen (combination of antimetabolite and platinum agent)	Thymidylate synthase (5-FU); DNA (oxaliplatin cross-linking)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen (combination of antimetabolite and platinum agent) class)

Kyungpook National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conventional adjuvant FOLFOX — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-adjuvant-folfox. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab